Downregulation of caveolin-1 increased EGFR-TKIs sensitivity in lung adenocarcinoma cell line with EGFR mutation

Biochemical and Biophysical Research Communications

Volumn 495, Issue 1, 2018, Pages 733-739

  Cui, Yujie ^a,d   Zhu, Tienian ^a,b   Song, Xuejing ^c   Liu, Jiankun ^b   Liu, Shuang ^b   Zhao, Ruijing ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^c FIRST HOSPITAL OF SHIJIAZHUANG   (China)

^d Hebei Genenral Hospital   (China)

Author keywords

Caveolin 1; EGFR; EGFR TKIs; Lung adenocarcinoma; Sensitivity

Indexed keywords

CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; CAV1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAV 1 GENE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; EGFR GENE; GENE; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG ADENOCARCINOMA CELL LINE; MOUSE; NONHUMAN; PC-9 CELL LINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAVEOLIN 1; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 85034435064     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.11.075     Document Type: Article

References (32)

1. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin. 65 (2015), 87–108.
2. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
3. Fukuoka, M., Wu, Y.L., Thongprasert, S., Sunpaweravong, P., Leong, S.S., Sriuranpong, V., Chao, T.Y., Nakagawa, K., Chu, D.T., Saijo, N., Duffield, E.L., Rukazenkov, Y., Speake, G., Jiang, H., Armour, A.A., To, K.F., Yang, J.C., Mok, T.S., Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29 (2011), 2866–2874.
4. Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12 (2011), 735–742.
5. Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., Ono, M., Overcoming drug resistance to receptor tyrosine kinase inhibitors: learning from lung cancer. Pharmacol. Ther. 161 (2016), 97–110.
6. Zhou, C., Yao, L.D., Strategies to improve outcomes of patients with EGRF-mutant non-small cell lung cancer: review of the literature. J. Thorac. Oncol. 11 (2016), 174–186.
7. Lee, D.H., Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures. Pharmacol. Ther. 174 (2017), 1–21.
8. Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., Bergethon, K., Shaw, A.T., Gettinger, S., Cosper, A.K., Akhavanfard, S., Heist, R.S., Temel, J., Christensen, J.G., Wain, J.C., Lynch, T.J., Vernovsky, K., Mark, E.J., Lanuti, M., Iafrate, A.J., Mino-Kenudson, M., Engelman, J.A., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3, 2011 75ra26.
9. Yu, H.A., Arcila, M.E., Rekhtman, N., Sima, C.S., Zakowski, M.F., Pao, W., Kris, M.G., Miller, V.A., Ladanyi, M., Riely, G.J., Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19 (2013), 2240–2247.
10. Cohen, A.W., Hnasko, R., Schubert, W., Lisanti, M.P., Role of caveolae and caveolins in health and disease. Physiol. Rev. 84 (2004), 1341–1379.
11. Sotgia, F., Martinez-Outschoorn, U.E., Howell, A., Pestell, R.G., Pavlides, S., Lisanti, M.P., Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu. Rev. Pathol. 7 (2012), 423–467.
12. Nunez-Wehinger, S., Ortiz, R.J., Diaz, N., Diaz, J., Lobos-Gonzalez, L., Quest, A.F., Caveolin-1 in cell migration and metastasis. Curr. Mol. Med. 14 (2014), 255–274.
13. Senetta, R., Stella, G., Pozzi, E., Sturli, N., Massi, D., Cassoni, P., Caveolin-1 as a promoter of tumour spreading: when, how, where and why. J. Cell Mol. Med. 17 (2013), 325–336.
14. Cai, C., Chen, J., Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int. J. Cancer 111 (2004), 522–529.
15. Lavie, Y., Fiucci, G., Liscovitch, M., Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J. Biol. Chem. 273 (1998), 32380–32383.
16. Morgensztern, D., Campo, M.J., Dahlberg, S.E., Doebele, R.C., Garon, E., Gerber, D.E., Goldberg, S.B., Hammerman, P.S., Heist, R.S., Hensing, T., Horn, L., Ramalingam, S.S., Rudin, C.M., Salgia, R., Sequist, L.V., Shaw, A.T., Simon, G.R., Somaiah, N., Spigel, D.R., Wrangle, J., Johnson, D., Herbst, R.S., Bunn, P., Govindan, R., Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J. Thorac. Oncol. 10 (2015), S1–S63.
17. Lavie, Y., Fiucci, G., Liscovitch, M., Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv. Drug Deliv. Rev. 49 (2001), 317–323.
18. Linge, A., Weinhold, K., Blasche, R., Kasper, M., Barth, K., Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells. Int. J. Biochem. Cell Biol. 39 (2007), 1964–1974.
19. Linge, A., Meleady, P., Henry, M., Clynes, M., Kasper, M., Barth, K., Bleomycin treatment of A549 human lung cancer cells results in association of MGr1-Ag and caveolin-1 in lipid rafts. Int. J. Biochem. Cell Biol. 43 (2011), 98–105.
20. Yang, C.P., Galbiati, F., Volonte, D., Horwitz, S.B., Lisanti, M.P., Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett. 439 (1998), 368–372.
21. Belanger, M.M., Gaudreau, M., Roussel, E., Couet, J., Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells. Cancer Biol. Ther. 3 (2004), 954–959.
22. Sekhar, S.C., Kasai, T., Satoh, A., Shigehiro, T., Mizutani, A., Murakami, H., El-Aarag, B.Y., Salomon, D.S., Massaguer, A., de Llorens, R., Seno, M., Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. J. Cancer 4 (2013), 391–401.
23. Liu, L., Xu, H.X., Wang, W.Q., Wu, C.T., Chen, T., Qin, Y., Liu, C., Xu, J., Long, J., Zhang, B., Xu, Y.F., Ni, Q.X., Li, M., Yu, X.J., Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene 33 (2014), 2728–2736.
24. Bender, F.C., Reymond, M.A., Bron, C., Quest, A.F., Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60 (2000), 5870–5878.
25. Wiechen, K., Diatchenko, L., Agoulnik, A., Scharff, K.M., Schober, H., Arlt, K., Zhumabayeva, B., Siebert, P.D., Dietel, M., Schafer, R., Sers, C., Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am. J. Pathol. 159 (2001), 1635–1643.
26. Williams, T.M., Hassan, G.S., Li, J., Cohen, A.W., Medina, F., Frank, P.G., Pestell, R.G., Di Vizio, D., Loda, M., Lisanti, M.P., Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J. Biol. Chem. 280 (2005), 25134–25145.
27. Thomas, S., Overdevest, J.B., Nitz, M.D., Williams, P.D., Owens, C.R., Sanchez-Carbayo, M., Frierson, H.F., Schwartz, M.A., Theodorescu, D., Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res. 71 (2011), 832–841.
28. Hu, Y.C., Lam, K.Y., Law, S., Wong, J., Srivastava, G., Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin. Cancer Res. 7 (2001), 3519–3525.
29. Sunaga, N., Miyajima, K., Suzuki, M., Sato, M., White, M.A., Ramirez, R.D., Shay, J.W., Gazdar, A.F., Minna, J.D., Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res. 64 (2004), 4277–4285.
30. Ho, C.C., Huang, P.H., Huang, H.Y., Chen, Y.H., Yang, P.C., Hsu, S.M., Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am. J. Pathol. 161 (2002), 1647–1656.
31. Pancotti, F., Roncuzzi, L., Maggiolini, M., Gasperi-Campani, A., Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal 24 (2012), 1390–1397.
32. Shtivelman, E., Hensing, T., Simon, G.R., Dennis, P.A., Otterson, G.A., Bueno, R., Salgia, R., Molecular pathways and therapeutic targets in lung cancer. Oncotarget 5 (2014), 1392–1433.